Media Articles Related to Qualaquin (Quinine)
Could global warming push malaria to higher elevations?
Source: Health News from Medical News Today [2014.03.07]
Each year, more than 300 million individuals are infected with malaria, a life-threatening blood disease caused by a parasite transmitted to humans by mosquitos. Whether malaria cases could be affected by warming climates has been a topic of debate, but now, researchers present the first evidence that the disease climbs to higher elevations during warmer years.The study, published in the journal Science, suggests future warming climate trends may prompt an increase in malaria cases, particularly in highly populated areas of Africa and South America that are at higher elevations.
Drug protects mice against malaria brain damage and raises levels of a neuroprotective factor in humans
Source: Neurology / Neuroscience News From Medical News Today [2014.03.06]
Cerebral malaria is a serious complication of infection with the malaria parasite, affecting approximately one in a thousand children in areas where malaria is common. Many of the patients die, and among those who survive, about a third have lasting cognitive and neurological disabilities, including epilepsy and learning disorders.
Nanoparticles as drug carriers for malaria
Source: Tropical Diseases News From Medical News Today [2014.03.03]
A study by researchers from the Institute for Bioengineering of Catalonia (IBEC) and the Barcelona Centre for International Health Research (CRESIB) demonstrates that an antimalarial drug encapsulated in nanoparticles - chloroquine salts in polyamidoamine polymers - is significantly more effective when delivered in vivo than free (unencapsulated) drugs and may help to curb drug resistance.
For malaria parasite transmission to mosquitos a key regulatory protein is essential
Source: Biology / Biochemistry News From Medical News Today [2014.02.25]
Malaria is caused by single-celled Plasmodium parasites. To survive and reproduce, these parasites have a rather complex lifecycle that involves three major stages.
Malaria: 57% of African population live in high-risk infection areas
Source: Blood / Hematology News From Medical News Today [2014.02.20]
In 2010, 90% of all malaria deaths occurred in populations living in the African region of the World Health Organization. Although the past 10 years have seen major investments in malaria control in Africa, new research suggests that almost 60% of the population continue to live in moderate- and high-risk infection areas.This is according to a study recently published in The Lancet.
Published Studies Related to Qualaquin (Quinine)
Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. [2011.06.02]
The development of immune cytopenias is a well-recognized side effect of many drugs...
Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda. [2011.02]
Quinine is a standard drug for treating severe malaria in Africa, and it is also increasingly used to treat uncomplicated disease. However, failures of quinine therapy are common, and it is unknown if failures in Africa are due to drug resistance... Our data suggest that quinine sensitivity is a complex trait and that known polymorphisms in pfcrt, pfmdr1, and pfnhe1, while associated with quinine sensitivity, are not robust markers for quinine resistance.
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. [2010.11.13]
BACKGROUND: Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate or quinine in African children with severe malaria... INTERPRETATION: Artesunate substantially reduces mortality in African children with severe malaria. These data, together with a meta-analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide. FUNDING: The Wellcome Trust. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. [2010.11]
BACKGROUND: Malaria in pregnancy is associated with maternal and fetal morbidity and mortality. In 2006, WHO recommended use of artemisinin-based combination treatments during the second or third trimesters, but data on efficacy and safety in Africa were scarce. We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda... INTERPRETATION: Artemisinin derivatives are not inferior to oral quinine for the treatment of uncomplicated malaria in pregnancy and might be preferable on the basis of safety and efficacy. FUNDING: Medecins Sans Frontieres and the European Commission. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria. [2010.09]
OBJECTIVE: This study was conducted to assess the effect of combination treatment of quinine and rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria... CONCLUSION: The study results suggest that addition of rabeprazole to quinine regimen resulted in an increase in the parasite elimination rate, which may be helpful in reducing the duration of treatment and increasing patient compliance.
Clinical Trials Related to Qualaquin (Quinine)
Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment [Recruiting]
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or
>50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active
metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy
subjects versus those with mild to moderate renal impairment will be compared, as well.
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria [Recruiting]
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to
investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for
example Arthemeter-Lumefantrine (AL) in Uganda (Ug) and artesunate-amodiaquine (ASAQ) in
RDCongo, on malaria incidence and its potential selection of resistant strains.
Patients will be followed-up for efficacy and safety during 42 days after treatment with the
first line therapy recommended by the national authorities(arthemeter-lumefantrine in Uganda
and artesunate-amodiaquine in RDCongo) and retreated the patients either with the same ACT
or an other ACT or oral Quinine + clyndamicin.
The investigators hypothesize that (re)treatment with the first line ACT treatment beyond 14
days is as efficacious as any other rescue treatment, without the risk of selecting drug
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine [Completed]
Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and
eliminated through the kidneys in HIV infected patients. Part II studies the effect of
probenecid and quinine on the same aspects.
Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep
adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT
leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT
needed for treatment.
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria [Active, not recruiting]
Cerebral malaria is the most lethal complication of P. falciparum infection with a mortality
rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral
malaria. However its administration is often not feasible due to lack of simple equipment or
trained staff. When referral is not possible, a viable alternative is needed. The intrarectal
route is of interest in children since it is painless and simple. Studies of the efficacy of
intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to
establish the efficacy of intrarectal quinine in the treatment of childhood cerebral
Reports of Suspected Qualaquin (Quinine) Side Effects
OFF Label USE (7),
Hearing Impaired (2),
Pruritus Generalised (1),
Oedema Peripheral (1),
Nervousness (1), more >>